BioRexis Pharmaceutical Corp., of King of Prussia, Pa., appointed Michael Celano vice president of finance and chief financial officer.
C.E. Unterberg, Towbin, of New York, appointed Matthew Osborne biotechnology analyst in the equity research department.
Cambrex Corp., of East Rutherford, N.J., appointed John Leone director, president and CEO, and Gary Mossman executive vice president and chief operating officer. Thomas Rohrer was named director, cell culture manufacturing of Cambrex's biopharmaceuticals business in Baltimore.
Celmed BioSciences Inc., of Montreal, appointed Pierre Marc Johnson chairman and Monique Lefebvre, Roger Headrick, Martijn Kleijwegt and Martial Lacroix to its board.
Cephalon Inc., of West Chester, Pa., promoted Natalie Barndt to vice president of business development, and appointed Ernest Kelly vice president of worldwide quality control. It also appointed Stephen Burns vice president of risk management.
Cerus Corp., of Concord, Calif., appointed William Dawson vice president of finance and chief financial officer.
Chiron Corp., of Emeryville, Calif., appointed Ursula Bartels vice president and general counsel.
Codexis Inc., of Redwood City, Calif., appointed Gerhard Mayr special adviser to its board.
Corcept Therapeutics Inc., of Menlo Park, Calif., appointed David Mahoney to its board.
CytRx Corp., of Los Angeles, appointed Jack Barber senior vice president of drug development; Benjamin Levin general counsel, vice president of legal affairs and corporate secretary; and Marvin Selter vice chairman of its board.
Elusys Therapeutics Inc., of Pine Brook, N.J., promoted Elizabeth Posillico to senior vice president of operations.
Entelos Inc., of Foster City, Calif., appointed Charles Sholtz vice president of legal affairs and intellectual property.
EPIX Medical Inc., of Cambridge, Mass., elected Gregory Phelps to its board.
Genaera Corp., of Plymouth Meeting, Pa., promoted John Armstrong to chief operating officer, John Skolas to executive vice president and Leanne Kelly to executive director of finance. It also appointed John McCloskey vice president of manufacturing and Laura Grablutz executive director of regulatory affairs.
Guava Technologies Inc., of Hayward, Calif., appointed David King vice president of product development.
Haemonetics Corp., of Braintree, Mass., re-elected Yutaka Sakurada to its board.